Identification of Lysine 74 in the Pyruvate Binding Site of Alanine Dehydrogenase from Bacillus subtilis
CHEMICAL MODIFICATION WITH 2,4,6-TRINITROBENZENESULFONIC ACID, N-SUCCINIMIDYL 3-(2-PYRIDYLDITHIO)PROPIONATE, AND 5'-(P-(FLUOROSULFONYL)BENZOYL)ADENOSINE*

(Received for publication, April 29, 1996, and in revised form, August 19, 1996)

Dominique Delforge Dagger , Bart Devreese §, Marc Dieu , Edouard Delaive , Jozef Van Beeumen § and José Remacle

From the Laboratory of Cellular Biochemistry, Facultés Universitaires Notre-Dame de la Paix, 61 rue de Bruxelles, B-5000 Namur, Belgium, and the § Department of Biochemistry, Physiology and Microbiology, Rijksuniversiteit, 35 Ledeganckstraat, B-9000 Gent, Belgium

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

L-Alanine dehydrogenase from Bacillus subtilis was inactivated with two different lysine-directed chemical reagents, i.e. 2,4,6-trinitrobenzenesulfonic acid and N-succinimidyl 3-(2-pyridyldithio)propionate. In both cases, the inactivation followed pseudo first-order kinetics, with a 1:1 stoichiometric ratio between the reagent and the enzyme subunits. Partial protection of the active site from inactivation could be obtained by each of the substrates, NADH or pyruvate, but complete protection could only be achieved in the presence of the ternary complex E·NADH·pyruvate. The nucleotide analogue of NADH, 5'-(p-(fluorosulfonyl)benzoyl)adenosine was also used for affinity labeling of the enzyme active site.

Differential peptide mapping, performed both in the presence and in the absence of the substrates, followed by reversed phase high performance liquid chromatography separation, diode-array analysis, mass spectrometry, and N-terminal sequencing of the resulting peptides, allowed the identification of lysine 74 in the active site of the enzyme. This residue, which is conserved among all L-alanine dehydrogenases, is most likely the residue previously postulated to be necessary for the binding of pyruvate in the active site.

Surprisingly, this residue and the surrounding conserved residues are not found in amino acid dehydrogenases like glutamate, leucine, phenylalanine, or valine dehydrogenases, suggesting that A-stereospecific amino acid dehydrogenases such as L-alanine dehydrogenase could have evolved apart from the B-stereospecific amino acid dehydrogenases.


INTRODUCTION

L-Alanine dehydrogenase (AlaDH1; EC 1.4.1.1) first identified by Wiame and Piérard (1), and later purified from Bacillus subtilis by Yoshida and Freese (2-4), catalyzes the reversible oxidative deamination of L-alanine to pyruvate and ammonium (Reaction R1).
<UP>NAD<SUP>+</SUP></UP>+<UP>H<SUB>2</SUB>O</UP>+<SC><UP>l</UP></SC><UP>-alanine &rlhar2; NH</UP><SUP><UP>+</UP></SUP><SUB><UP>4</UP></SUB>+<UP>pyruvate</UP>+<UP>NADH</UP>+<UP>H<SUP>+</SUP></UP>
<SC><UP>Reaction</UP></SC> 1
In Bacillus species this enzyme is known to play a key role in the generation of pyruvate as energy source during sporulation (5, 6). The kinetic properties of the enzyme have been elucidated (7), together with the mechanism (8) and the limiting steps of the catalysis (9). These studies showed that the B. subtilis alanine dehydrogenase follows predominately an ordered mechanism in which NAD+ binds before L-alanine. The products are released in the order ammonia and pyruvate before NADH. The hydrogen transfer to NAD+ during catalysis has been shown to occur at the pro(R) position of the nicotinamide ring, indicating that B. subtilis AlaDH is a member of the A-stereospecific dehydrogenases (10).

The amino acid sequence of AlaDH has been first determined from the strains Bacillus sphaericus and Bacillus stearothermophilus (11). The sequence fingerprint characteristic of the beta alpha beta Rossmann's fold responsible for the nucleotide binding (12, 13) has been recognized. Alignment of AlaDH sequences with other amino acid dehydrogenases like glutamate dehydrogenase, leucine dehydrogenase, or phenylalanine dehydrogenase, and with hydroxyacid dehydrogenases like lactate dehydrogenase or malate dehydrogenase led Kuroda et al. (11) to propose His-153 and Lys-156 to be part of the catalytic site. However, the availability of a third AlaDH sequence, obtained from Mycobacterium tuberculosis (14) did not support this hypothesis and stressed the need to investigate the composition of the active site (15).

Sequence comparisons between AlaDH and other proteins available in data banks have shown high similarities between AlaDH and the N-terminal part of pyridine nucleotide transhydrogenase (15, 16), for which a three-dimensional model of the NAD+ binding site has been proposed (17). However, no convincing sequence resemblance between AlaDH and the other enzymes of the amino acid dehydrogenase superfamily has been found. In that respect, AlaDH constitutes an exception from the other amino acid dehydrogenases, like glutamate dehydrogenase, whose three-dimensional structure has been elucidated (18), or leucine dehydrogenase, phenylalanine dehydrogenase, and valine dehydrogenase, which have been shown to share sequence and structure similarities with glutamate dehydrogenase (19, 20). These similarities include an identical B-type stereospecificity with respect to NAD+ (21-23) and a common organization of the residues implicated in the catalytic chemistry (19).

We have much information on the active-site structure of B-stereospecific amino acid dehydrogenases, obtained by chemical modification studies (24-28), by genetic engineering (27, 29-32), and from x-ray crystallographic data (18, 33, 34). However, very scarce information is available for the A-stereospecific amino acid dehydrogenases such as alanine dehydrogenase. Little is known about the residues that might be involved in substrate binding and catalysis (8, 35, 36), and no catalytic amino acid residue has been identified. Recently, the amino acid sequence from B. subtilis alanine dehydrogenase has become available (6), allowing the interpretation of chemical modification studies performed on this enzyme.

In this paper, we provide evidence that Lys-74 of B. subtilis alanine dehydrogenase is located at the active site of the enzyme. That residue is conserved among all alanine dehydrogenases sequenced so far and is likely the lysine residue that is required for the binding of pyruvate during the catalytic reaction.


EXPERIMENTAL PROCEDURES

Materials

L-Alanine dehydrogenase from B. subtilis purchased from Sigma was desalted before use on a 15 × 2.5-cm Ultrogel AcA44 column (IBF Biotechnics, Villeneuve-la-Garenne, France) equilibrated in 100 mM NaH2PO4, pH 7.5. The substrates NADH and pyruvate and the chemical reagents 2,4,6-trinitrobenzenesulfonic acid (TNBS), N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), and 5'-(p-(fluorosulfonyl)benzoyl) adenosine (FSBA) were also obtained from Sigma. Endoproteinase Glu-C sequencing grade was from Boehringer (Mannheim, Germany). All other reagents were from Merck (Darmstadt, Germany), except Tris, guanidine HCl, and trifluoroacetic acid, which were from Acros Chimica (Beerse, Belgium), and acetonitrile, which was from Carlo Erba (Milano, Italy).

Assays

Alanine dehydrogenase activity was assayed for alanine synthesis according to Yoshida et al. (3). In typical experiments, the assay mixture (0.6 ml) contained 0.5 mM NADH, 2 mM pyruvate, and 100 mM NH4Cl in 100 mM Tris-HCl, pH 8.5. The reaction was started by the addition of 1-2 µg of protein to the mixture. The assay was carried out at 20 °C by recording the decrease in absorbance of NADH at 340 nm, with a Kontron 930 variable wavelength spectrophotometer. Protein assay was performed by the Folin reagent method (37), using bovine serum albumin as standard. When the samples contained Tris-HCl as buffer, the protein concentration was determined by the dye binding assay (38), using the kit provided by Bio-Rad (München, Germany).

Chemical Modification with TNBS

AlaDH was inactivated by incubating the enzyme (1 mg/ml) in the dark, at 40 °C, in the presence of varying concentrations of TNBS (39) (stock solutions diluted in ice-cold distilled water), in 100 mM NaH2PO4, pH 8.0. Aliquots (2 µl) were removed at regular time intervals and mixed with the assay solution to measure residual activity. Control experiment showed that the enzyme did not loose any activity in those conditions when TNBS was omitted.

Chemical Modification with SPDP

Inactivation by SPDP (40) was also performed at a protein concentration of 1 mg/ml, in 100 mM NaH2PO4, but the pH was adjusted to 7.5 and the experiment was carried out at 20 °C during 10 min. SPDP at varying concentrations was dissolved in ethanol before addition to the protein solution. Residual activity was also assayed at different times as indicated above. A control experiment showed that the enzyme did not lose any activity when the experiment was performed in the same conditions as without SPDP. In the pH conditions mentioned, chemical modification by SPDP is known to be specific for primary amino groups (epsilon -NH2 group of lysines or N-terminal NH2-group of the protein) rather than for cysteines (40). However, we performed a control experiment by incubating SPDP-inactivated AlaDH in 25 mM NaH2PO4, pH 7.8, in the presence of 5 mM dithiothreitol at 20 °C (45 min), in order to check the possible reaction of SPDP with a putative active-site cysteine of the enzyme.

Chemical Modification with FSBA

AlaDH (1 mg/ml) was inactivated by FSBA (41) at varying reagent concentrations (stock solution dissolved in dimethyl sulfoxide) in 100 mM NaH2PO4, pH 7.5, at 40 °C (in the dark), and the activity was measured at time intervals. Also here, the enzyme showed no loss of activity in the incubation conditions when FSBA was omitted.

Protection Studies

The ability of substrates to protect the active site of the enzyme from inactivation was estimated by testing the effect of NADH and/or pyruvate. Except when indicated otherwise in the text, alanine dehydrogenase was at 1 mg/ml and NADH·pyruvate was added at a final concentration of 0.44 mM (100 × molar excess with respect to enzyme concentration) and 44 mM (10,000 × molar excess), respectively, before the start of the chemical modification.

Proteolysis of Chemically Modified Alanine Dehydrogenase

Several samples of alanine dehydrogenase (1.2-2.0 mg; 1 mg/ml; 4.4 µM) were modified separately with the chemical reagents TNBS, SPDP, or FSBA in the above mentioned conditions. Reagent concentrations and incubation times were, respectively, 0.88 mM (60 min), 0.44 mM (10 min), and 1.76 mM (30 min) for TNBS, SPDP, and FSBA modification. After the reaction, AlaDH was separated from the chemicals by chromatography on an Ultrogel AcA44 column (2.5 cm × 15 cm; IBF Biotechnics, Villeneuve-la-Garenne, France) equilibrated with 25 mM NaH2PO4, pH 7.8. The enzyme was then reconcentrated over a PM10 ultrafiltration membrane in a Centricon concentration system from Amicon (Lexington, MA). Protein concentration was adjusted to 1.2 mg/ml, and 6 M guanidine HCl in 25 mM NaH2PO4, pH 7.8, was added to the solution at a ratio of 20:100 (v/v). Digestion was achieved using endoproteinase Glu-C (42) (1 mg/ml) at a ratio of 1:50 (w/w) relative to the enzyme, during 16 h at 25 °C. The digest (400 µl to 1 ml) was then analyzed on a reversed phase HPLC. A control experiment with native AlaDH was performed in parallel, in exactly the same conditions.

Separation and Detection of Peptides

Peptides resulting from enzymatic cleavage were separated by reversed phase HPLC on a C18 Nucleosil column (Macherey-Nagel, Düren, Germany), using the HP1090 HPLC system (Hewlett-Packard, Palo Alto, CA) equipped with a 1040M Series II multiple wavelength diode-array detector. Samples (1 mg/ml, 500 µl) were filtered through a 0.2-µm membrane Nylon Acrodisc (Gelman Sciences, Ann Arbor, MI) before injection onto the column previously equilibrated with solvent A. The gradient used was 0-20% B for 5 min (elution of guanidine HCl and buffer), followed by 20-80% B for 72 min (elution of the peptides), and a wash by 100% B during 15 min. Solvent A was trifluoroacetic acid 0.1% (v/v) in water, solvent B was trifluoroacetic acid 0.1% (v/v) in water-acetonitrile (20:80). Elution was carried out at a flow rate of 1 ml/min, with the multiple wavelength detector, respectively, set at 220/280/346, 220/280/304, and 220/280/259 nm for TNBS-, SPDP-, and FSBA-labeled samples. Control experiments were also performed by injecting the reagents alone under the same chromatographic conditions. Eluted peptides were collected and either frozen at -70 °C or lyophilized for further analysis.

Peptide Repurification

When necessary, peptides of interest were further purified by HPLC under the same chromatographic conditions, except that a linear gradient of 0.25% increase of solvent B/min was used. Alternatively, peptides were repurified on a C18 column from Pharmacia (Uppsala, Sweden) using the Pharmacia Smart system with a linear gradient of 0-70% solvent B over 45 min.

Mass Analysis of Peptides and Amino Acid Sequence Determination

Peptides of interest were dissolved in acetonitrile/1% acetic acid in water (50:50) and their mass determined in a VG Platform electrospray ionization mass spectrometer (Fisons Instruments, Manchester, United Kingdom). The amino acid sequence of peptides was determined on a model 475A peptide sequencer (Applied Biosystems, Foster City, CA) equipped with on-line phenylthiohydantoin-derivative analyzer.


RESULTS

Chemical Modification by TNBS and SPDP

TNBS and N-hydroxysuccinimide esters like SPDP are known to be highly selective reagents at pH 7.5-8.0 for the modification of lysine residues (epsilon -NH2 group of the side chain) and/or N terminus of proteins (39, 40). Incubation of L-alanine dehydrogenase with varying concentrations of TNBS and SPDP resulted in a time-dependent loss of enzyme activity, suggesting the modification of a primary amino group located at or near the enzyme active site. Plots of the logarithm of remaining activity versus time at different reagent concentrations indicated in each case pseudo first-order kinetics (Figs. 1A and 2A). A straight line was also observed for the plot of pseudo first-order rate constants versus reagent concentration (Figs. 1B and 2B), indicating that the chemical modification is the result of a simple bimolecular reaction. The second-order rate constants (kinact) obtained for the modification by TNBS and SPDP were 0.57 and 60.6 M-1 s-1, respectively, and show a much higher reactivity of SPDP compared to TNBS toward the active-site lysine residue. Plotting log kinact versus log of reagent concentration, according to Levy et al. (43), yields an apparent reaction order of 0.88 and 1.00 for TNBS and SPDP, respectively, indicating that inactivation results from the reaction of approximately 1 mol of reagent with 1 mol of enzyme subunit (Figs. 1C and 2C). This observation is in agreement with the result obtained for the stoichiometry of the reaction with SPDP, which indicates that the modification of no more than 1.4 lysine residues/monomer is required for the complete inactivation of AlaDH (Fig. 3).


Fig. 1. Inactivation of alanine dehydrogenase with TNBS. A, L-alanine dehydrogenase (1 mg/ml, 4.4 × 10-3 mM, 60 µl) in 100 mM NaH2PO4, pH 8.0 (40 °C), was incubated in the dark with no (bullet ), 10 × (open circle ), 20 × (black-square), 50 × (black-triangle), 100 × (square ), and 200 × (triangle ) molar excess of reagent relative to the enzyme (hexamer) concentration. Samples (2 µl) were removed every 5 min, and residual activity was determined. Pseudo first-order rate constants of inactivation kinact are obtained from the slopes of straight lines fitted to data points by least square linear regression. B, determination of the second-order rate constant of inactivation. C, determination of apparent order of reaction with respect to reagent concentration.
[View Larger Version of this Image (27K GIF file)]



Fig. 2. Inactivation of alanine dehydrogenase with SPDP. A, L-alanine dehydrogenase (1 mg/ml, 4.4 × 10-3 mM, 60 µl) in 100 mM NaH2PO4, pH 7.5 (20 °C), was incubated with no (bullet ), 2.5 × (open circle ), 5 × (black-square), 10 × (black-triangle), 25 × (square ), and 50 × (triangle ) molar excess of reagent relative to the enzyme (hexamer) concentration. Samples (2 µl) were removed every minute, and residual activity was determined. See Fig. 1 legend for details.
[View Larger Version of this Image (27K GIF file)]



Fig. 3. Stoichiometry of chemical modification of AlaDH with SPDP. AlaDH (1 mg/ml, 4.4 × 10-3 mM, 60 µl) in 100 mM NaH2PO4, pH 7.5 (20 °C), was incubated with different molar excesses of reagent relative to monomer concentration. After 20 min of incubation (end of reaction), samples (2 µl) were removed and residual activity was assayed. Assuming a chemical modification with a 100% yield, the number of modified residues per monomer for complete inactivation can be estimated by extrapolating the straight line fitted to the first data points (bullet ) to zero activity.
[View Larger Version of this Image (20K GIF file)]


SPDP is a bifunctional reagent that can also react with cysteine residues to form a disulfide link (40). In order to estimate the possible involvement of cysteine reaction, we incubated SPDP-inactivated AlaDH in the presence of 5 mM dithiothreitol (45 min, 20 °C) to determine whether reduction of the enzyme could restore its activity. Only 17.5% of activity could be restored by this treatment, assessing that inactivation with SPDP was mainly the result of modification of a lysine rather than a cysteine residue.

Chemical Modification with FSBA

In a third series of experiments, we used the structural analog of NADH, FSBA, for specific modification of the alanine dehydrogenase cofactor binding site. This reagent has proved to be appropriate for active-site affinity labeling of other dehydrogenases like malate dehydrogenase, 20beta -hydroxysteroid dehydrogenase, or 17beta -estradiol dehydrogenase (41). The time course of AlaDH inactivation in the presence of FSBA followed pseudo first-order kinetics (Fig. 4A), but, in this case, complete inactivation of the enzyme could not be obtained even at high reagent concentration. The activity declined to a non-zero value after a relatively long period (60 min of incubation). A minimum residual activity of about 25% was obtained with 10 mM FSBA (Fig. 5A). The rate of inactivation increased according to the initial FSBA concentration, showing typical saturation kinetics. This is observed in the plot of pseudo first-order rate constants kinact versus FSBA concentration (Fig. 4B) and in the plot of log kinact versus log FSBA concentration (Fig. 4C), where a deviation from linearity is observed at high reagent concentrations. Fitting straight lines by linear regression on the linear portion of data points gave values of 5.47 × 10-2 M-1 s-1 and 0.76 for the second-order rate constant and the apparent order of reaction, respectively, but a polynomial second-order curve best fitted the data points in Fig. 4B with a correlation coefficient of R2 = 1.00. These results clearly show that chemical modification of AlaDH with FSBA does not follow a simple bimolecular mechanism as observed for TNBS or SPDP but proceeds through a two-step reaction. This is in agreement with a mechanism where FSBA first binds to the adenosine binding site of the enzyme to form a reversible non-covalent complex (inhibition) and subsequently reacts in an irreversible covalent way with an amino acid residue of the active site (inactivation) (Reaction R2).
E+<UP>FSBA</UP> <LIM><OP><ARROW>&rlhar2;</ARROW></OP><LL>k<SUB>2</SUB></LL><UL>  k<SUB>1</SUB>  </UL></LIM> E · <UP>FSBA</UP> <LIM><OP><ARROW>→</ARROW></OP><UL>  k<SUB>3</SUB>  </UL></LIM> E-<UP>FSBA</UP>
          <AR><R><C><UP>non-covalent</UP></C></R><R><C><UP>complex</UP></C></R><R><C>(<UP>inhibition</UP>)</C></R></AR>
 <AR><R><C></C></R><R><C><UP>covalent</UP></C></R><R><C><UP>complex</UP></C></R><R><C>(<UP>inactivation</UP>)</C></R></AR>
<SC><UP>Reaction</UP></SC> 2
For this reason, results were analyzed according to the method of Kitz and Wilson (44) for irreversible inhibitors, where the observed rate constant for inactivation is as shown in Equation 1.
k<SUB><UP>inact</UP></SUB>=<FR><NU>[<UP>FSBA</UP>] · k<SUB>3</SUB></NU><DE>[<UP>FSBA</UP>]+K<SUB>I</SUB></DE></FR> (Eq. 1)
The double-reciprocal plot according to this method, 1/kinact versus 1/[FSBA], gives a straight line (Fig. 5B).
<FR><NU>1</NU><DE>k<SUB><UP>inact</UP></SUB></DE></FR>=<FR><NU>K<SUB>I</SUB></NU><DE>k<SUB>3</SUB> [<UP>FSBA</UP>]</DE></FR>+<FR><NU>1</NU><DE>k<SUB>3</SUB></DE></FR> (Eq. 2)
KI and k3 were calculated as being 2.26 mM and 2.36 × 10-4 s-1, respectively (R2 = 0.96).


Fig. 4. Inactivation of alanine dehydrogenase with FSBA. A, L-alanine dehydrogenase (1 mg/ml, 4.4 × 10-3 mM, 60 µl) in 100 mM NaH2PO4, pH 7.5 (40 °C), was incubated in the dark with 100 × (bullet ), 200 × (open circle ), 500 × (black-square), 1000 × (black-triangle), 2000 × (square ), and 5000 × (triangle ) molar excess of reagent relative to the enzyme (hexamer) concentration. Samples (2 µl) were removed every 5 min, and residual activity was determined. Pseudo first-order rate constants of inactivation kinact are obtained from the slopes of straight lines fitted to data points by least square linear regression. B, determination of second-order rate constant of inactivation. Linear regression was only performed on the linear portion of data points (bullet ). C, apparent order of reaction with respect to reagent concentration, determined by linear least square regression on the linear portion of data points (bullet ).
[View Larger Version of this Image (28K GIF file)]



Fig. 5. Inactivation of alanine dehydrogenase with FSBA. A, plot of the final residual activity of the enzyme after 60 min of incubation in the presence of FSBA as a function of the initial reagent concentration. B, double-reciprocal plot of 1/kinact versus 1/[FSBA] allowing the determination of KI and k3. Values of kinact were determined from the plots of Fig. 4A.
[View Larger Version of this Image (17K GIF file)]


Protection Studies

In order to assess that the chemical modification by TNBS, SPDP, and FSBA is active-site directed, we tested the ability of substrates to protect the enzyme active site from inactivation (Fig. 6). The mechanism of reaction of AlaDH is known to be ordered with first the binding of NADH, followed by pyruvate and ammonium (7). We could not assay the protection by L-alanine or NH4Cl since they can react with the chemical reagents used. We tested the protecting effect of NADH, pyruvate, and pyruvate analogues. In the case of TNBS and SPDP, only little or no protecting effect was observed when the substrates NADH or pyruvate were used alone. However, the kinact was dramatically reduced when NADH and pyruvate were used together. This result clearly shows that the lysine residue reacting with these chemicals is located in the active site of the enzyme and can only be protected in the presence of the ternary complex E·NADH·pyruvate. The inability of NADH alone to protect the enzyme from inactivation suggest that it does not occur at the NADH binding site itself but more likely at or near the pyruvate binding site of the enzyme as the presence of pyruvate is also required for good protection. The inability of pyruvate alone to protect from inactivation can be understood by the ordered mechanism of reaction in which pyruvate can only bind to the enzyme when NADH is first fixed at the active site.


Fig. 6. Protection of alanine dehydrogenase by NADH and pyruvate against chemical modification with TNBS, SPDP, and FSBA. Alanine dehydrogenase (1 mg/ml in 100 mM NaH2PO4, pH 7.5) was incubated in the presence of TNBS 0.88 mM (200-fold molar excess) (A), SPDP 0.44 mM (100-fold molar excess) (B), FSBA 8.77 mM (2000-fold molar excess) (C), without protection by the substrates (bullet ), in the presence of 0.44 mM NADH (100-fold molar excess) (open circle ), in the presence of 44 mM pyruvate (10,000-fold molar excess) (black-square) and in the presence of 0.44 mM NADH and 44 mM pyruvate (black-triangle). The molar excess is calculated relative to the enzyme (hexamer) concentration.
[View Larger Version of this Image (16K GIF file)]


We then tested the ability of several pyruvate analogues in combination with NADH to protect AlaDH from inactivation, in order to see whether there was a correlation between the ability of these compounds to act as substrates and to afford protection against the lysine modification (Table I). The results show that increasing the length of the aliphatic chain of ketoacids from methyl (in pyruvate) to propyl (in alpha -ketovalerate) gradually reduces the protecting effect of the substrates. Replacing the methyl group of pyruvate by a hydrogen (in glyoxylate) or a carboxylic acid chain (in the dicarboxylic acid series) completely abolishes the protecting effect, except for oxalacetate, which exhibits a strikingly high protecting effect. These results confirm the presence of the lysine residue near the pyruvate binding site since oxalacetate is a good substrate for the enzyme, the product of the reaction being D-aspartate and not L-aspartate as it could be expected (data not shown). This is in contrast to the other dicarboxylic acids which are not accepted as substrates. Finally, replacing the methyl group of pyruvate by -NH2 in oxamate gave some protection against inactivation. This is also in agreement with the fact that oxamate is an isosteric and isoelectronic substrate analogue of pyruvate and is known to be a competitive inhibitor of alanine dehydrogenase (7).

Table I.

Protection of alanine dehydrogenase by substrates and analogues during inactivation with SPDP

Alanine dehydrogenase (20 µg/ml) in 100 mM NaH2PO4, pH 7.5 (20 °C), was inactivated with 22 µM SPDP (250 × molar excess). Residual activity was determined after 10 min of incubation. Protection was achieved by incubating 17.5 µM NADH (200 × molar excess), and 1.75 mM pyruvate or pyruvate analogues (20,000 × molar excess) before the start of the chemical modification. Molar excess is calculated relative to the enzyme (hexamer) concentration.
Protecting substrates and analogues Structure HOOC-CO-R kinact Residual activity Protecting effecta Kmb

10-2 min-1 % % mM
No protection 10.31 12.1 <0
Pyruvate 8.86 15.2 <0 0.53
NADH 2.83 53.7 0  2.3 × 10-2
NADH + glyoxylate R = -H 3.23 20.6 <0 16
NADH + pyruvate R = -CH3 0.48 89.2 100 0.53
NADH + alpha -ketobutyrate R = -CH2-CH3 1.66 71.5 50 23
NADH + alpha -ketovalerate R = -(CH2)2-CH3 2.68 58.3 6 33
NADH + oxalate R = -OH 2.77 54.7 2
NADH + mesoxalate R = -COOH 3.24 49.6 <0
NADH + oxalacetate R = -CH2-COOH 1.57 70.2 53 6.5c
NADH + alpha -ketoglutarate R = -(CH2)2-COOH 3.14 51.3 <0
NADH + oxamate R = -NH2 2.04 67.7 33 d

a  The protecting effect is calculated in procent relative to the protective effect of NADH + pyruvate taking the protecting effect of NADH alone as being zero.
b  In 5 mM Tris·HCl, pH 8.0 (25 °C), according to Ref. 3.
c  Determined by ourselves in 100 mM Tris·HCl, pH 8.5 (20 °C).
d  Inhibition constant for oxamate in 50 mM Tes, pH 7.9 (25 °C), KI = 4.1 mM, according to Ref. 7.

Similar results for substrate protection were obtained for FSBA inactivation, except that here a greater effect was obtained for the protection by NADH alone (Fig. 6C). This observation is in agreement with the fact that, because of its structural similarity to NADH, FSBA is expected to bind at the NADH binding site before its covalent reaction with an amino acid of the active site. Nevertheless, here again the simultaneous presence of both NADH and pyruvate is required for a complete protection against inactivation.

Identification of Modified Amino Acid Residues

L-Alanine dehydrogenase was chemically modified using TNBS, SPDP, and FSBA as described under "Experimental Procedures." Samples were passed through a desalting column, reconcentrated, and submitted to proteolysis using endoproteinase Glu-C (42). For TNBS and SPDP inactivation, experiments were carried out in parallel both in the presence of NADH and pyruvate (protection of the whole active site) or in the presence of NADH alone (protection of the NADH binding site only).

The HPLC profiles obtained for TNBS-modified alanine dehydrogenase are presented in Fig. 7. The comparison of the profiles shows that the peak eluting at 32.5 min disappears when pyruvate is absent from the active site (Fig. 7, A and B, peak I), while another peak eluting at 46.0 min increases (peak II). This increase is particularly obvious at 346 nm (Fig. 7D), which is a specific wavelength for TNBS chemical modification. Diode-array detection analysis of these compounds indicated that peak II was labeled with TNBS, while peak I was not, as shown by its characteristic absorbance profile with a maximum at 346 and 420 nm (Fig. 8A). Peptides from peaks I and II were collected and submitted to mass determination and to N-terminal sequencing (over 6-10 residues) by automated Edman degradation. For the peak eluting at 32.5 min, the sequence MVMKVK could be identified (Table II). This result, together with the mass determination obtained (Mr = 2286.8) indicates that peptide I corresponds to Met-69 to Lys-86 (Table III). Interestingly, a similar sequence was found in the peptidic fragments identified in peak II, where the mass observed for one of these two fragments was consistent with the TNBS labeling of the peptide Met-69-Lys-86 (Table II, fragment IIa). Unfortunately, only a few phenylthiohydantoin-derivatives of this fragment could be identified due to the low amount of material available, but they all corresponded to the expected sequence. Another peptidic fragment (Table II, fragment IIb), starting with a proline corresponding to Pro-76 in the AlaDH sequence, contaminated peak II.


Fig. 7. Reversed phase HPLC profile of the peptides resulting from endoproteinase Glu-C proteolysis of TNBS-modified L-alanine dehydrogenase. A and C, chemical modification in the presence of NADH and pyruvate (protection of the whole active site); B and D, chemical modification in the presence of NADH alone (protection of the NADH binding site only). Arrows indicate active-site peptides. Mass determinations: peptide from peak I, Mr = 2286.8; peptides from peak II, Mr = 2498.5 and 3374.5.
[View Larger Version of this Image (30K GIF file)]



Fig. 8. Absorbance profile of peaks I-IV (Figs. 7, 9, and 10) determined by diode-array detection during the elution of the peaks. Dotted lines, unmodified peptide eluting at 32.5 min (peak I, Fig. 7A) with a maximum of absorbance at 278 nm characteristic of Tyr- or Phe-containing peptides. Continuous lines: A, peptides eluting at 46.0 min (peak II, Fig. 7B), with a maximum of absorbance at 346 and 420 nm characteristic of TNBS labeling (39); B, peptide eluting at 39.8 min (peak III, Fig. 9B), with a maximum absorbance difference at 304 nm characteristic of SPDP labeling (40); C, peptide eluting at 36.3 min (peak IV, Fig. 10D) with a maximum absorbance difference at 259 nm characteristic of FSBA labeling (41).
[View Larger Version of this Image (21K GIF file)]


Table II.

Sequence of the active-site peptide fragments resulting from endoproteinase Glu-C proteolysis of chemically modified L-alanine dehydrogenase

The letter X denotes an unidentified amino acid residue. Asterisks indicate an amino acid residue whose PTH-derivative has an unusual retention time, corresponding to a chemically modified PTH-amino acid derivative. Calculated Mr values are: peptide fragment Met-69-Lys-86 from B. subtilis alanine dehydrogenase = 2286.8; TNBS labeling = +211.1; SPDP labeling = +197.3 (oxidized), +88.1 (reduced); FSBA labeling = +467.3.
Sample (peak) Chemical modification N-terminal sequence Masses observed

I None MVMKVK 2286.8
IIa TNBS XVXXV*XPLPEEYV 2498.5
IIb TNBS PLPEEYXYFR 3374.5
III SPDP MVMKV*EP 2374.2, 2484.8, and 3912.1 
IV FSBA MVMKV*EPLP 2721.0 and 3883.0

Table III.

Alignment of the active-site peptide fragment with the sequences of L-alanine dehydrogenase and pyridine nucleotide transhydrogenase

The asterisk indicates the lysine residue modified during the chemical labeling of the L-alanine dehydrogenase active site. Outlined letters denote residues conserved among all alanine dehydrogenases sequenced to date. The number of the first and last residue of each sequence is given, respectively, at the beginning and end of each line. Residues EEGTD, PTLGVH, PTLGAH, and PTLGVH, are, respectively, in the original sequences of Rhodospirillum rubrum, Bos taurus, Mus musculus, and Homo sapiens pyridine nucleotide transhydrogenases before the conserved glutamate residue.

The HPLC profile of the peptides obtained after chemical modification of alanine dehydrogenase with SPDP is presented in Fig. 9. Similarly to the results obtained in Fig. 7, the peak eluting at Rt = 32.5 min (peak I) decreases when pyruvate is absent from the active site, while another peak increases, which absorbs at 304 nm (Fig. 8B) and elutes at Rt = 39.8 min (Fig. 9, peak III). This result suggests that the SPDP chemical labeling modified the same peptidic fragment of alanine dehydrogenase as the one modified with TNBS, i.e. Met-69 to Lys-86. This was also confirmed by the mass analysis and sequence determination of the peptides contained in peak III (Table II), where masses of 2484.8 and 2374.2 are in agreement with the SPDP-labeling of peptide I (in the oxidized and reduced states), while the mass of 3912.1 is consistent with a longer SPDP-labeled fragment from Met-69 to Glu-99. The N-terminal sequencing of the peptide from peak III gave the consensus sequence MVMKV*EP, with an unidentified phenylthiohydantoin-derivative at the 6th cycle, corresponding to Lys-74 in L-alanine dehydrogenase (Table II).


Fig. 9. Reversed phase HPLC profile of the peptides resulting from the endoproteinase Glu-C proteolysis of SPDP-modified L-alanine dehydrogenase. A and C, chemical modification in the presence of NADH and pyruvate (protection of the whole active site); B and D, chemical modification in the presence of NADH alone (protection of the NADH binding site only). Arrows indicate active-site peptides. Mass determination: peptides from peak III, Mr = 2374.2, 2484.8, and 3912.1.
[View Larger Version of this Image (27K GIF file)]


The elution pattern of the peptides resulting from endoproteinase Glu-C digest of FSBA-labeled alanine dehydrogenase (Fig. 10) was obtained similarly to those obtained after the TNBS and SPDP chemical modification, except that the experiment was performed both in the presence of NADH and pyruvate (protection of the whole active site) and without any substrate (no protection). This reagent, which potentially can react with several residues of the active site, also reacted with the same peptidic fragment as indicated by the decrease of peak I when the substrates were omitted (Fig. 10, A and B). Peak IV appearing in those conditions highly absorbs at 259 nm (Fig. 8C and 10D) and gave the sequence MVMKV*EPLP, with masses of 2721.0 and 3883.0 (Table II).


Fig. 10. Reversed phase HPLC profile of the peptides resulting from the endoproteinase Glu-C proteolysis of FSBA-modified L-alanine dehydrogenase. A and C, chemical modification in the presence of NADH and pyruvate (protection of the active site); B and D, chemical modification without substrates (no protection). Arrows indicate active-site peptides. Mass determination: peptides from peak IV, Mr = 2721.0 and 3883.0.
[View Larger Version of this Image (27K GIF file)]



DISCUSSION

L-Alanine dehydrogenase from B. subtilis was completely inactivated using TNBS and SPDP. In both cases, the inactivation of the enzyme was the result of a simple bimolecular reaction, with the modification of about one lysine residue/monomer. This result suggests the presence of an essential lysine residue at or near the active site of the enzyme. A different pattern of inactivation was obtained for the modification of AlaDH with the structural analogue of NADH, i.e. FSBA. In this case, saturation kinetics were obtained, indicating a two-step mechanism where FSBA binds to the NADH binding site of the enzyme before irreversible chemical modification of an active-site residue. Results obtained for the chemical modification of the enzyme in the presence of the substrates indicate that NADH or pyruvate alone do not allow a good protection, and that the enzyme can only be effectively protected when the ternary complex E·NADH·pyruvate is formed. Given the ordered mechanism of AlaDH where NADH binds before pyruvate (7), the fact that both NADH and pyruvate are required for a good protection of the active site suggests that the chemical modification occurs at the pyruvate binding site, rather than at the NADH binding site.

Differential peptide mapping, both in the presence and in the absence of the substrates, and monitoring at a wavelength specific for the label, allowed the identification of active-site peptide fragments. For both TNBS and SPDP, the same peptidic fragment from Met-69 to Lys-86 was found to be labeled, with a concomitant retention time modification and increase of absorbance of the corresponding peak. Sequence comparisons of the isolated fragments with the known sequence of B. subtilis alanine dehydrogenase (6) indicated that the cleavage between Glu-68 and Met-69 is consistent with the expected cleavage specificity of endoproteinase Glu-C, i.e. the cleavage after Glu or Asp residues (42). On the other hand, the absence of cleavage after Glu-75, Glu-79, and Glu-80 is probably due to the presence of two proline residues, respectively, at position 76 and 78 of the sequence. These residues are known to form secondary structures that often prevent the recognition of proteases with their substrates. More surprising was the aspecific cleavage of endoproteinase Glu-C after a lysine residue in position 86, which was obtained for several independent experiments. This unusual cleavage after a lysine residue is not in the list of the several aspecific cleavages that have been reported for endoproteinase Glu-C, for example after Gly and Ala (45), Asn and Tyr (46), or Gln and Ser (47). To our knowledge, cleavage after a lysine had not yet been observed.

Mass and sequence determinations of the isolated peptides were consistent with the chemical labeling of lysine 74 of the L-alanine dehydrogenase, implying the presence of this residue at or near the active site of the enzyme. Interestingly, the active-site affinity labeling using FSBA also modified the same Met-69-Lys-86 peptidic fragment at the position of lysine 74, although FSBA can react with several residues other than lysine. Sequence alignment of this peptide with the known sequences of B. subtilis AlaDH (6), B. sphaericus (11), B. stearothermophilus (11), M. tuberculosis (14), and Synechocystis sp. (48) indicates that the modified lysine residue is conserved among all the alanine dehydrogenases sequenced to date, and that it is located in an important stretch of five conserved residues KVKEP from Lys-72 to Pro-76 (Table III). According to the sequence analysis of the enzyme (15), these residues are most likely located outside of the NADH binding site, which is supposed to expand around and after the characteristic GXGXXG(X17)D motif of the beta alpha beta Rossmann's fold. This observation is in agreement with a localization of Lys-74 at the pyruvate binding site but in close vicinity of the NADH binding site, since the same Lys-74 is also modified by FSBA. The presence of Lys-74 in the NADH binding site itself is not completely excluded. In this case, the protection obtained for the enzyme inactivation by TNBS and SPDP, only when both NADH and pyruvate are present, would implicate that Lys-74 would still be accessible to these chemicals when NADH alone is bound to the active site, but that a conformational change occurs when pyruvate is bound, so that only in this situation, Lys-74 would be part of the NADH binding site. This possibility cannot be ruled out, but all the arguments presented here above argue against this explanation.

According to Grimshaw et al. (8), a cationic acid group on the enzyme (probably a lysine) is required for effective binding of the substrate and the inhibitors, while another cationic acid group (probably a histidine), acts as an acid-base catalyst of the reaction. In an attempt to locate these residues in the sequence of B. sphaericus and B. stearothermophilus, Kuroda et al. (11) performed sequence comparisons with other amino acid dehydrogenases (glutamate dehydrogenase, phenylalanine dehydrogenase, and leucine dehydrogenase) and with hydroxyacid dehydrogenase, which share some substrate and catalytic features with alanine dehydrogenase (lactate dehydrogenase and malate dehydrogenase). In their conclusions, the authors proposed His-153 and Lys-156 from B. sphaericus to be part of the active site (11, 27). However, the availability of a third alanine dehydrogenase obtained from M. tuberculosis (14) ruled out this hypothesis, since the proposed residues were not conserved in this new sequence (15). The experimental results obtained by us clearly identify Lys-74 as part of the enzyme active site, and support its role in the catalytic mechanism of the L-alanine dehydrogenase.

In a previous paper the sequence of B. sphaericus alanine dehydrogenase was compared with the protein sequences of the Swissprot, GenBank, and EMBL data bases (15). Surprisingly, no other amino acid dehydrogenase or hydroxyacid dehydrogenase was found to be significantly similar to alanine dehydrogenase, but the enzyme was found to be similar to the N-terminal sequence of pyridine nucleotide transhydrogenase, suggesting a similar folding of these two protein segments (15). However, no alanine dehydrogenase activity was detected in M. tuberculosis pyridine nucleotide transhydrogenase (56), suggesting that even if they have a similar structure, their active site is different. In agreement with this active-site difference, pyridine nucleotide transhydrogenase also lacks lysine 74, which was found to be essential for the activity of alanine dehydrogenase (Table III).

L-Alanine dehydrogenases appear as very unique enzymes among the amino acid dehydrogenases. Alanine dehydrogenase has been shown to be a member of A-stereospecific dehydrogenases (10, 57), unlike the other amino acid dehydrogenases studied to date, which are B-stereospecific (21-23). In this paper, we showed that alanine dehydrogenases from B. subtilis posses a lysine at the position 74 that is essential for the enzyme activity, and that this residue is conserved among the other alanine dehydrogenases sequenced so far (Table III). This lysine and the surrounding conserved sequence region are not found in other dehydrogenases. Furthermore, the characteristic active-site motif K(X8)GGXK identified in glutamate, leucine, phenylalanine, and valine dehydrogenases (19, 20) is not found in L-alanine dehydrogenases, suggesting a separate evolution of these two groups of amino acid dehydrogenases. The only similarity of sequence was found with one part of the pyridine nucleotide transhydrogenase, which suggests that L-alanine dehydrogenase, contrary to the B-stereospecific amino acid dehydrogenases, may have evolved along with pyridine nucleotide transhydrogenases rather than with the other dehydrogenases of the amino acid dehydrogenase superfamily.


FOOTNOTES

*   The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Supported by a fellowship from the Institute for Scientific Research in Industry and Agriculture, Brussels, Belgium, and by grants from the Facultés Universitaires Notre-Dame de la Paix, Namur, Belgium. To whom correspondence should be addressed. Tel.: 32-81-72-41-28; Fax: 32-81-72-41-35.
   Recipient of Concerted Research Action Grant 12052293 from the Flemish Department for Scientific Research.
1    The abbreviations used are: AlaDH, alanine dehydrogenase; FSBA, 5'-(p-(fluorosulfonyl)benzoyl)adenosine; HPLC, high performance liquid chromatography; Rt, retention time; SPDP, N-succinimidyl 3-(2-pyridyldithio)propionate; TNBS, 2,4,6-trinitrobenzenesulfonic acid.

Acknowledgments

We gratefully acknowledge John D. Shannon from the University of Virginia for information on nonspecific cleavages by endoproteinase Glu-C.


REFERENCES

  1. Wiame, J. M., and Piérard, A. (1955) Nature 176, 1073-1075 [Medline] [Order article via Infotrieve]
  2. Yoshida, A., and Freese, E. (1964) Biochim. Biophys. Acta 92, 33-43 [Medline] [Order article via Infotrieve]
  3. Yoshida, A., and Freese, E. (1965) Biochim. Biophys. Acta 96, 248-262
  4. Yoshida, A., and Freese, E. (1970) Methods Enzymol. 17, 176-181
  5. McCowen, S. M., and Phibbs, P. V., Jr. (1974) J. Bacteriol. 118, 590-597 [Medline] [Order article via Infotrieve]
  6. Siranosian, K. J., Ireton, K., and Grossman, A. D. (1993) J. Bacteriol. 175, 6789-6796 [Abstract]
  7. Grimshaw, C. E., and Cleland, W. W. (1981) Biochemistry 20, 5650-5655 [Medline] [Order article via Infotrieve]
  8. Grimshaw, C. E., Cook, P. F., and Cleland, W. W. (1981) Biochemistry 20, 5655-5661 [Medline] [Order article via Infotrieve]
  9. Weiss, P. M., Chen, C.-Y., Cleland, W. W., and Cook, P. F. (1988) Biochemistry 27, 4814-4822 [Medline] [Order article via Infotrieve]
  10. Alizade, M., Bressler, R., and Brendel, K. (1975) Biochim. Biophys. Acta 397, 5-8 [Medline] [Order article via Infotrieve]
  11. Kuroda, S., Tanizawa, K., Sakamoto, Y., Hidehiko, T., and Soda, K. (1990) Biochemistry 29, 1009-1015 [Medline] [Order article via Infotrieve]
  12. Wierenga, R. K., Terpstra, P., and Hol, W. G. J. (1986) J. Mol. Biol. 187, 101-107 [Medline] [Order article via Infotrieve]
  13. Bork, P., and Grunwald, C. (1990) Eur. J. Biochem. 191, 347-358 [Abstract]
  14. Andersen, Å. B., Andersen, P., and Ljungqvist, L. (1992) Infect. Immun. 60, 2317-2323 [Abstract]
  15. Delforge, D., Depiereux, E., De Bolle, X., Feytmans, E., and Remacle, J. (1993) Biochem. Biophys. Res. Commun. 190, 1073-1079 [CrossRef][Medline] [Order article via Infotrieve]
  16. Cunningham, I. J., Williams, R., Palmer, T., Thomas, C. M., and Jackson, J. B. (1992) Biochim. Biophys. Acta 1100, 332-338 [Medline] [Order article via Infotrieve]
  17. Fjellström, O., Olausson, T., Hu, X., Källebring, B., Ahmad, S., Bragg, P. D., and Rydström, J. (1995) Proteins Struct. Funct. Genet. 21, 91-104 [Medline] [Order article via Infotrieve]
  18. Baker, P. J., Britton, K. L., Engel, P. C., Farrants, G. W., Lilley, K. S., Rice, D. W., and Stillman, T. J. (1992) Proteins Struct. Funct. Genet. 12, 75-86 [Medline] [Order article via Infotrieve]
  19. Britton, K. L., Baker, P. J., Engel, P. C., Rice, D. W., and Stillman, T. J. (1993) J. Mol. Biol. 234, 938-945 [CrossRef][Medline] [Order article via Infotrieve]
  20. Tang, L., and Hutchinson, C. R. (1993) J. Bacteriol. 175, 4176-4185 [Abstract]
  21. Smith, E. L., Austen, B. L., Blumenthal, K. M., and Nyc, J. F. (1975) The Enzymes, 3rd Ed., Vol. 11, Part A, pp. 293-367, Academic Press, New York
  22. Nagata, S., Tanizawa, K., Esaki, N., Sakamoto, Y., Ohshima, T., Tanaka, H., and Soda, K. (1988) Biochemistry 27, 9056-9062 [Medline] [Order article via Infotrieve]
  23. Okazaki, N., Hibino, Y., Asano, Y., Ohmori, M., Numano, N., and Kondo, K. (1988) Gene (Amst.) 63, 337-341 [Medline] [Order article via Infotrieve]
  24. Piszkiewicz, D., Landon, M., and Smith, E. L. (1970) J. Biol. Chem. 245, 2622-2626 [Abstract/Free Full Text]
  25. Chen, S.-S., and Engel, P. C. (1975) Biochem. J. 149, 619-626 [Medline] [Order article via Infotrieve]
  26. Lilley, K. S., and Engel, P. C. (1992) Eur. J. Biochem. 207, 533-540 [Abstract]
  27. Matsuyama, T., Soda, K., Fukui, T., and Tanizawa, K. (1992) J. Biochem. (Tokyo) 112, 258-265 [Abstract]
  28. Syed, S. E.-H., Hornby, D. P., Brown, P. E., Fitton, J. E., and Engel, P. C. (1994) Biochem. J. 298, 107-113 [Medline] [Order article via Infotrieve]
  29. Jones, K. M., McPherson, M. J., Baron, A. J., Mattaj, I. W., Riordan, C. L., and Wootton, J. C. (1993) Mol. Gen. Genet. 240, 286-289 [Medline] [Order article via Infotrieve]
  30. Sekimoto, T., Matsuyama, T., Fukui, T., and Tanizawa, K. (1993) J. Biol. Chem. 268, 27039-27045 [Abstract/Free Full Text]
  31. Sekimoto, T., Fukui, T., and Tanizawa, K. (1994) J. Biol. Chem. 269, 7262-7266 [Abstract/Free Full Text]
  32. Dean, J. L. E., Wang, X.-G., Teller, J. K., Waugh, M. L., Britton, K. L., Baker, P. J., Stillman, T. J., Martin, S. R., Rice, D. W., and Engel, P. C. (1994) Biochem. J. 301, 13-16 [Medline] [Order article via Infotrieve]
  33. Britton, K. L., Baker, P. J., Rice, D. W., and Stillman, T. J. (1992) Eur. J. Biochem. 209, 851-859 [Abstract]
  34. Stillman, T. J., Baker, P. J., Britton, K. L., and Rice, D. W. (1993) J. Mol. Biol. 234, 1131-1139 [CrossRef][Medline] [Order article via Infotrieve]
  35. Matsui, K., Fukuda, K., and Kameda, Y. (1981) Chem. Pharm. Bull. 29, 485-489 [Medline] [Order article via Infotrieve]
  36. Delforge, D., and Remacle, J. (1993) Arch. Int. Phys. Biochem. Biophys. 101, B34
  37. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275 [Free Full Text]
  38. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  39. Fields, R. (1972) Methods Enzymol. 25, 464-468
  40. Carlsson, J., Drevin, H., and Axén, R. (1978) Biochem. J. 173, 723-737 [Medline] [Order article via Infotrieve]
  41. Colman, R. F. (1983) Annu. Rev. Biochem. 52, 67-91 [CrossRef][Medline] [Order article via Infotrieve]
  42. Drapeau, G. R. (1977) Methods Enzymol. 47, 189-191 [Medline] [Order article via Infotrieve]
  43. Levy, H. M., Leber, P. D., and Ryan, E. M. (1963) J. Biol. Chem. 238, 3654-3659 [Free Full Text]
  44. Kitz, R., and Wilson, I. B. (1962) J. Biol. Chem. 237, 3245-3249 [Free Full Text]
  45. Dognin, M. J., and Wittmann-Liebold, B. (1977) FEBS Lett. 84, 342-346 [CrossRef][Medline] [Order article via Infotrieve]
  46. Moonen, P., Akeroyd, R., Westerman, J., Puijk, W. C., Smits, P., and Wirtz, K. W. A. (1980) Eur. J. Biochem. 106, 279-290 [Abstract]
  47. McWherter, C. A., Thannhauser, T. W., Fredrickson, R. A., Zagotta, M. T., and Scheraga, H. A. (1984) Anal. Biochem. 141, 523-537 [Medline] [Order article via Infotrieve]
  48. Kaneko, T., Sato, S., Kotani, H., Tanaka, A., Asamizu, E., Nakamura, Y., Miyajima, N., Hirosawa, M., Sugiura, M., Sasamoto, S., et al. (1996) DNA Res. 3, 109-136 [Medline] [Order article via Infotrieve]
  49. Ahmad, S., Glavas, N. A., and Bragg, P. D. (1992) Eur. J. Biochem. 207, 733-739 [Abstract]
  50. Fleischmann, R. D., Adams, M. D., White, O., Clayton, R. A., Kirkness, E. F., Kerlavage, A. R., Bult, C. J., Tomb, J.-F., Dougherty, B. A., Merrick, J. M., et al. (1995) Science 269, 496-512 [Medline] [Order article via Infotrieve]
  51. Williams, R., Cotton, N. P. J., Thomas, C. M., and Jackson, J. B. (1994) Microbiology 140, 1595-1604 [Abstract]
  52. Yu, Y., and Samuelson, J. (1994) Mol. Biochem. Parasitol. 68, 323-328 [Medline] [Order article via Infotrieve]
  53. Wilson, R., Ainscough, R., Anderson, K., Baynes, C., Berks, M., Bonfield, J., Burton, J., Connell, M., Copsey, T., Cooper, J., et al. (1994) Nature 368, 32-38 [CrossRef][Medline] [Order article via Infotrieve]
  54. Yamaguchi, M., Hatefi, Y., Trach, K., and Hoch, J. A. (1988) J. Biol. Chem. 263, 2761-2767 [Abstract/Free Full Text]
  55. Arkblad, E. L., Betsholtz, C., and Rydstrom, J. (1996) Biochim. Biophys. Acta 1273, 203-205 [Medline] [Order article via Infotrieve]
  56. Deshpande, R. G., Khan, M. B., Bhat, D. A., and Navalkar, R. G. (1994) J. Appl. Bacteriol. 77, 639-643 [Medline] [Order article via Infotrieve]
  57. Glasfeld, A., Leanz, G. F., and Benner, S. A. (1990) J. Biol. Chem. 265, 11692-11699 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.